Working... Menu

Serial Changes in sTREM-1 During Ventilator-associated Pneumonia (VAP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00976157
Recruitment Status : Completed
First Posted : September 14, 2009
Last Update Posted : September 15, 2009
Information provided by:
Mackay Memorial Hospital

Brief Summary:
Triggering receptor expressed on myeloid cells (TREM)-1 is a recently described molecule that plays an important role in myeloid cell-activated inflammatory responses. The aim of this study was to investigate the evolutional change of soluble TREM-1 (sTREM-1) in bronchoalveolar lavage (BAL) fluid of clinically diagnosed ventilator-associated pneumonia (VAP) and its correlation with response to treatment and outcome.

Condition or disease Intervention/treatment
Pneumonia Procedure: Bronchoscopy BAL

Detailed Description:
A prospective, interventional study conducted between August 2006 and August 2007 in MICU in Mackay Memorial Hospital, 35 patients with clinically diagnosed VAP were investigated. sTREM-1 was measured in BAL samples using ELISA at the onset, 4th - 5th and 7th - 9th day of clinical diagnosis of VAP.Of these 35 patients, 27 had positive BAL culture. The sTREM-1 levels in BAL fluid were measured and compared between patients with positive BAL culture and negative BAL culture. Serial changes in sTREM-1 levels were evaluated in relation to patient outcome.

Layout table for study information
Study Type : Observational
Actual Enrollment : 35 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Serial Changes of Soluble TREM-1 Level in Bronchoalveolar Lavage Fluid During Ventilator-associated Pneumonia
Study Start Date : August 2006
Actual Primary Completion Date : December 2007
Actual Study Completion Date : September 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Pneumonia

Group/Cohort Intervention/treatment
Ventilator-associated pneumonia Procedure: Bronchoscopy BAL
The bronchoscope was passed through endotracheal tube via a specific adaptor without topical anesthesia. The bronchoscope was introduced and wedged into the segmental bronchial orifice where pneumonia was suspected. Five aliquots of 20ml sterile saline were instilled and aspirated gently. The first aliquot was discarded and the last 4 aliquots were pooled for analysis. Part of the retrieved specimen in the first BAL fluid was sent to the laboratory immediately after collection for measurement of sTREM-1 level, the rest of sample was sent to microbiology lab for quantitative culture.

Primary Outcome Measures :
  1. mortality [ Time Frame: 18 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 86 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients who were clinically suspected to have VAP were enrolled in the study. VAP was clinically diagnosed with a new infiltrate on a chest radiograph in a patient receiving mechanical ventilation for more than 48 hr with at least one of the following: purulent tracheal secretions, a body temperature >38°C or <36°C, and leukocytosis (WBC > 10,000/mm³) or leukopenia (WBC < 4000/mm³)

Inclusion Criteria:

  • adult patients (older than 18 years)with clinically suspected VAP

Exclusion Criteria:

  • mechanically ventilated patients post cardiopulmonary resuscitation
  • patients with end stage diseases with life expectancy less than 3 months
  • patients with solid or hematology transplantation
  • patients on immunosuppressive agents

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00976157

Layout table for location information
Mackay Memorial Hospital
Taipei, Taiwan, 106
Sponsors and Collaborators
Mackay Memorial Hospital
Layout table for investigator information
Principal Investigator: Chien Liang Wu, MD Mackay Memorial Hospital, Taipei, Taiwan

Layout table for additonal information
Responsible Party: Cheng-Ho Tsai,superintendent, Mackay Memorial Hospital Identifier: NCT00976157     History of Changes
Other Study ID Numbers: MMH-I-S-201
First Posted: September 14, 2009    Key Record Dates
Last Update Posted: September 15, 2009
Last Verified: September 2009

Keywords provided by Mackay Memorial Hospital:

Additional relevant MeSH terms:
Layout table for MeSH terms
Pneumonia, Ventilator-Associated
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Cross Infection